AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.47
-0.20 (-3.53%)
Jul 24, 2026, 11:31 AM EDT - Market open
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $10.5. The average 1-year stock price forecast is 91.96% higher than the current stock price, while the lowest is $7.00 (+27.97%) and the highest is $13 (+137.66%).
Price Target: $10.5 (+91.96%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $7 → $11 | Buy | Maintains | $7 → $11 | +101.10% | Jul 17, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $13 | Buy | Maintains | $13 | +137.66% | Jul 15, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $7 | Buy | Maintains | $7 | +27.97% | Jun 18, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $10 → $12 | Buy | Reiterates | $10 → $12 | +119.38% | May 22, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $7 → $8 | Buy | Reiterates | $7 → $8 | +46.25% | May 12, 2026 |
Financial Forecast
Revenue This Year
31.62M
from 75.13M
Decreased by -57.91%
Revenue Next Year
34.14M
from 31.62M
Increased by 7.98%
EPS This Year
-0.63
from -0.49
EPS Next Year
-0.71
from -0.63
EPS and Forward PE are based on non-GAAP adjusted numbers.